Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (CURES-104)

Journal of Postgraduate Medicine

Volumn 57, Issue 4, 2011, Pages 272-277

  Subashini, R ^a   Deepa, M ^a   Padmavati, R ^b   Thara, R ^b   Mohan, V ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

^b SCHIZOPHRENIA RESEARCH FOUNDATION   (India)

Author keywords

Impaired fasting glucose; metabolic syndrome; obesity; schizophrenia; south India; type 2 diabetes

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; GLUCOSE; HALOPERIDOL; LIPID; OLANZAPINE; RISPERIDONE; TRIFLUOPERAZINE;

ABDOMINAL OBESITY; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY WEIGHT; CASE CONTROL STUDY; CHI SQUARE TEST; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; SCHIZOPHRENIA; STUDENT T TEST; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INDIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PREVALENCE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84855214439     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.90075     Document Type: Article

References (41)

1. International Diabetes Federation Diabetes Atlas. Unwin N, Whiting D, Gan D, Jacqmain O, Ghyoot G, editors. IDF Diabetes Atlas. 4th ed. Belgium: International Diabetes Federation; 2009. p. 11-3.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. (Pubitemid 38579764)
3. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The study of health assessment and risk in ethnic groups [SHARE]. Lancet 2000;356:279-84. (Pubitemid 30459585)
4. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48:345-7. (Pubitemid 36841274)
5. Dixon L, Weiden P, Delahany J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
6. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004;6:74-7.
7. Saari KM, Linderman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A fourfold risk of metabolic syndrome in patients with schizophrenia: The northern Finland 1966 birth cohort study. J Clin Psychiatry 2005;66:559-63. (Pubitemid 40733696)
8. Mattoo SK, Singh SM. Prevalence of metabolic syndrome in psychiatric inpatients in a tertiary care centre in north India. Indian J Med Res 2010;131:46-52.
9. Heiskhanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9. (Pubitemid 36618288)
10. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology(ESC). Eur Psychiatry 2009;24:412-24.
11. Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S, et al. The Chennai Urban Rural Epidemiology Study [CURES] - Study Design and Methodology [Urban Component] [CURES - 1]. J Assoc Physicians India 2003;51:863-70. (Pubitemid 41279865)
12. Mohan V, Deepa M, Deepa R, Shanthirani CS, Farooq S, Ganesan A, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban south India - the Chennai Urban Rural Epidemiology Study [CURES-17]. Diabetologia 2006;49:1175-8.
13. Mohan V, Deepa M, Farooq S, Narayan KM, Datta M, Deepa R. Anthropometrics cut points for identification of cardiometabolic risk factors in an urban Asian Indian population. Metabolism 2007;56:961-8. (Pubitemid 46890980)
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27 Suppl 1: S5-S10.
15. International Diabetes Federation [2005]. New IDF worldwide definition of the metabolic syndrome. Press Conference, 1st International Congress on 'Pre-diabetes' and the Metabolic Syndrome, Berlin, Germany, Available from: http://www.idf.org, [Last accessed on 2005 Apr 14].
16. Hägg S, Joelsson L, Mjörndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients with clozapine compared to with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-9. (Pubitemid 28353977)
17. Cohen D, Puite B, Dekker J, Gispen De Wied C. Diabetes mellitus in 93 chronic schizophrenic inpatients. Eur J Psychiatry 2003;17:38-47. (Pubitemid 36676095)
18. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia, A, et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009;194:434-8.
19. Mohan V, Deepa M, Deepa R, Shanthirani CS, Farooq S, Ganesan A, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban south India - the Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia 2006;49:1175-8.
20. Rayan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first episode, drug - native patients with schizophrenia. Am J Psychiatry 2003;160:284-9. (Pubitemid 41110453)
21. Gourdy P, Ruidavets JB, Ferrieres J, Ducimetiere P, Amouyel P, Arveiler D, et al. Prevalence of type 2 diabetes and impaired fasting glucose in the middle aged population of three French regions - the MONICA study 1995-1997. Diabetes Metab 2001;27:347-58.
22. Deepa R, Sandeep S, Mohan V. Abdominal obesity, visceral fat and Type 2 diabetes - Asian Indian Phenotype. In: Mohan V, Rao GH, editor. Type 2 Diabetes in South Asians: Epidemiology, Risk Factors and Prevention. Under the Aegis of SASAT. New Delhi: Jaypee Brothers Medical Publishers; 2006. p. 138-52.
23. Silversstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988;153:214-7.
24. Hsiao CC, Ree SC, Chiang YL, Yeh SS, Chen CK. Obesity in schizophrenia outpatients receiving antipsychotics in Taiwan. Psychiatry Clin Neurosci 2004;58:403-9.
25. Misra A, Khurana L. The metabolic syndrome in South Asians: Epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009;7:497-514.
26. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians; the Chennai urban rural epidemiology study (CURES-34). Diabetes Metab Res Rev 2007;23:12-34.
27. McEvoy JP, Mayer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of metabolic syndrome in patients with schizophrenia: Baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Res 2005;80:19-32. (Pubitemid 41587460)
28. Bermudes RA, Keck PE Jr, Welge JA. The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics 2006;47:491-7. (Pubitemid 44657599)
29. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007;29:330-6. (Pubitemid 351358057)
30. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychoticinduced type 2 diabetes: Evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-5. (Pubitemid 36951173)
31. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003;59:1-6. (Pubitemid 35284487)
32. Allison DB, Fortatine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individual with and without schizophrenia. J Clin Psychiatry 1999;60:215-20. (Pubitemid 29193917)
33. Harrington C, Gregorian R, Gemmen E, Hughes C, Golden K, Robinson G, et al. Access and utilization of new antidepressant and antipsychotic medications. Falls Church, VA: Lewin Group; 2000.
34. Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71:244-54. (Pubitemid 35007648)
35. Henderson D. Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs 2002;16:77-89. (Pubitemid 34155205)
36. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-13. (Pubitemid 39209683)
37. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 2007;68 Suppl 1:20-7.
38. American Diabetes Associations, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity. Diabetes Care 2004;27:596-601.
39. Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: Minimal model analysis. Metabolism 2000;49:1255-60.
40. Mohan V, Deepa R, Deepa M, Somannavar S, Datta M. A simplified Indian diabetes risk score for screening for undiagnosed diabetic subjects. J Assoc Physicians India 2005;53:759-63. (Pubitemid 41365556)
41. Mohan V, Sandeep S, Deepa M, Gokulakrishnan K, Datta M, Deepa R. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians-?the Chennai Urban Rural Epidemiology Study (CURES-38). Diabetes Obes Metab 2007;9:337-43. (Pubitemid 46502052)